Download
s12072-021-10193-8.pdf 1,18MB
WeightNameValue
1000 Titel
  • Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial
1000 Autor/in
  1. Vogl, T. J. |
  2. Langenbach, M. C. |
  3. Hammerstingl, R. |
  4. Albrecht, M. H. |
  5. Chatterjee, A. R. |
  6. Gruber-Rouh, Tatjana |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-05-27
1000 Erschienen in
1000 Quellenangabe
  • 15(3):685-694
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12072-021-10193-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286929/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!This prospective randomized trial is designed to compare the performance of conventional transarterial chemoembolization (cTACE) using Lipiodol-only with additional use of degradable starch microspheres (DSM) for hepatocellular carcinoma (HCC) in BCLC-stage-B based on metric tumor response.!##!Methods!#!Sixty-one patients (44 men; 17 women; range 44-85) with HCC were evaluated in this IRB-approved HIPPA compliant study. The treatment protocol included three TACE-sessions in 4-week intervals, in all cases with Mitomycin C as a chemotherapeutic agent. Multiparametric magnetic resonance imaging (MRI) was performed prior to the first and 4 weeks after the last TACE. Two treatment groups were determined using a randomization sheet: In 30 patients, TACE was performed using Lipiodol only (group 1). In 31 cases Lipiodol was combined with DSMs (group 2). Response according to tumor volume, diameter, mRECIST criteria, and the development of necrotic areas were analyzed and compared using the Mann-Whitney-U, Kruskal-Wallis-H-test, and Spearman-Rho. Survival data were analyzed using the Kaplan-Meier estimator.!##!Results!#!A mean overall tumor volume reduction of 21.45% (± 62.34%) was observed with an average tumor volume reduction of 19.95% in group 1 vs. 22.95% in group 2 (p = 0.653). Mean diameter reduction was measured with 6.26% (± 34.75%), for group 1 with 11.86% vs. 4.06% in group 2 (p = 0.678). Regarding mRECIST criteria, group 1 versus group 2 showed complete response in 0 versus 3 cases, partial response in 2 versus 7 cases, stable disease in 21 versus 17 cases, and progressive disease in 3 versus 1 cases (p = 0.010). Estimated overall survival was in mean 33.4 months (95% CI 25.5-41.4) for cTACE with Lipiosol plus DSM, and 32.5 months (95% CI 26.6-38.4), for cTACE with Lipiodol-only (p = 0.844), respectively.!##!Conclusions!#!The additional application of DSM during cTACE showed a significant benefit in tumor response according to mRECIST compared to cTACE with Lipiodol-only. No benefit in survival time was observed.
1000 Sacherschließung
lokal TACE
lokal Aged, 80 and over [MeSH]
lokal Lipiodol
lokal Aged [MeSH]
lokal Liver Neoplasms/therapy [MeSH]
lokal Mitomycin C
lokal Carcinoma, Hepatocellular/therapy [MeSH]
lokal Original Article
lokal Randomized Controlled Trials as Topic [MeSH]
lokal Survival
lokal Male [MeSH]
lokal Starch [MeSH]
lokal Magnetic resonance imaging
lokal Female [MeSH]
lokal Response
lokal Necrotic area
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Hepatocellular carcinoma
lokal Treatment Outcome [MeSH]
lokal Tumor volume
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal DSM
lokal Ethiodized Oil [MeSH]
lokal Chemoembolization, Therapeutic [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Vm9nbCwgVC4gSi4=|https://frl.publisso.de/adhoc/uri/TGFuZ2VuYmFjaCwgTS4gQy4=|https://frl.publisso.de/adhoc/uri/SGFtbWVyc3RpbmdsLCBSLg==|https://frl.publisso.de/adhoc/uri/QWxicmVjaHQsIE0uIEgu|https://frl.publisso.de/adhoc/uri/Q2hhdHRlcmplZSwgQS4gUi4=|https://orcid.org/0000-0001-9724-7744
1000 Hinweis
  • DeepGreen-ID: d9afd7d3f3a2422ebf6433d0af2632e7 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6445610.rdf
1000 Erstellt am 2023-04-28T10:48:44.971+0200
1000 Erstellt von 322
1000 beschreibt frl:6445610
1000 Zuletzt bearbeitet 2023-10-20T15:53:54.558+0200
1000 Objekt bearb. Fri Oct 20 15:53:54 CEST 2023
1000 Vgl. frl:6445610
1000 Oai Id
  1. oai:frl.publisso.de:frl:6445610 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source